AbstractUsing a novel approach that detects changes in the conformation of ERα, we studied the efficacy of anti-estrogens to inactivate ERα under different experimental conditions. We show that phosphorylation of serine-305 in the hinge region of ERα by protein kinase A (PKA) induced resistance to tamoxifen. Tamoxifen bound but then failed to induce the inactive conformation, invoking ERα-dependent transactivation instead. PKA activity thus induces a switch from antagonistic to agonistic effects of tamoxifen on ERα. In clinical samples, we found that downregulation of a negative regulator of PKA, PKA-RIα, was associated with tamoxifen resistance prior to treatment. Activation of PKA by downregulation of PKA-RIα converts tamoxifen from an ER...
Tamoxifen provided a successful treatment for ER-positive breast cancer for many years. However, mos...
The mechanisms responsible for 17β-estradiol (E2)-stimulated breast cancer growth and development of...
Cancer is the number one cause of mortality worldwide. Breast cancer is the most common type of canc...
AbstractUsing a novel approach that detects changes in the conformation of ERα, we studied the effic...
Background: Estrogen Receptor alpha (ERaα)-positive breast cancer patients receive endocrine therapy...
About two thirds of all human breast cancer cases are estrogen receptor positive. ...
Background: Estrogen Receptor alpha (ERα)-positive breast cancer patients receive endocrine therapy,...
Background Tamoxifen still remains the most frequently used antioestrogen for the treatment of br...
Antiestrogen resistance is a major clinical problem in the treatment of breast cancer. Altered growt...
Breast cancer is one of the most highly diagnosed cancers in women and the second largest cause of d...
The efficacy of anti-estrogen therapy in breast cancer is confined by the occurrence of intrinsic or...
Anti-estrogen therapies like tamoxifen are the most successful breast cancer treatments to date. How...
Abstract Background The estrogen receptor (ER) inhibi...
Phosphorylation of estrogen receptor alpha at serine 305 (ER alpha S305-P) by protein kinase A (PKA)...
Antiestrogen resistance often develops with prolonged exposure to hormone therapies, including tamox...
Tamoxifen provided a successful treatment for ER-positive breast cancer for many years. However, mos...
The mechanisms responsible for 17β-estradiol (E2)-stimulated breast cancer growth and development of...
Cancer is the number one cause of mortality worldwide. Breast cancer is the most common type of canc...
AbstractUsing a novel approach that detects changes in the conformation of ERα, we studied the effic...
Background: Estrogen Receptor alpha (ERaα)-positive breast cancer patients receive endocrine therapy...
About two thirds of all human breast cancer cases are estrogen receptor positive. ...
Background: Estrogen Receptor alpha (ERα)-positive breast cancer patients receive endocrine therapy,...
Background Tamoxifen still remains the most frequently used antioestrogen for the treatment of br...
Antiestrogen resistance is a major clinical problem in the treatment of breast cancer. Altered growt...
Breast cancer is one of the most highly diagnosed cancers in women and the second largest cause of d...
The efficacy of anti-estrogen therapy in breast cancer is confined by the occurrence of intrinsic or...
Anti-estrogen therapies like tamoxifen are the most successful breast cancer treatments to date. How...
Abstract Background The estrogen receptor (ER) inhibi...
Phosphorylation of estrogen receptor alpha at serine 305 (ER alpha S305-P) by protein kinase A (PKA)...
Antiestrogen resistance often develops with prolonged exposure to hormone therapies, including tamox...
Tamoxifen provided a successful treatment for ER-positive breast cancer for many years. However, mos...
The mechanisms responsible for 17β-estradiol (E2)-stimulated breast cancer growth and development of...
Cancer is the number one cause of mortality worldwide. Breast cancer is the most common type of canc...